Access
To read this story in full you will need to login or make a payment (see right).
News
Nature 419, 767 (24 October 2002) | doi:10.1038/419767b
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Assistant Professor of Medicine
- Massachusetts General Hospital
- Boston, MA
Lectureship in Ecology
- University of Southampton
- Southampton, Hampshire, SO16 7PX, UK
Malta provides loophole for breast-cancer screen
Erika Check
A Maltese biotechnology firm is set to challenge the potential monopoly on breast-cancer screening held by US company Myriad Genetics.Synergene, which was set up in Malta in 2000, claims to have found a loophole in Myriad's patents, and says that it will launch a diagnostic test for breast cancer next January.
To read this story in full you will need to login or make a payment (see right).
